These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 29853342)

  • 21. Historical development of the concept of controlling cardiac arrhythmias by lengthening repolarization: particular reference to sotalol.
    Singh BN
    Am J Cardiol; 1990 Jan; 65(2):3A-11A; discussion 35A-36A. PubMed ID: 2403733
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sotalol: a new beta-adrenergic blocker for ventricular arrhythmias.
    Cavusoglu E; Frishman WH
    Prog Cardiovasc Dis; 1995; 37(6):423-40. PubMed ID: 7777671
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effect of sotalol on exercise-induced ventricular arrhythmias.
    Petzl DH; Probst P; Glogar D; Schuster E
    Eur Heart J; 1988 Mar; 9(3):265-70. PubMed ID: 3383867
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pediatric Dosing of Intravenous Sotalol Based on Body Surface Area in Patients with Arrhythmia.
    Li X; Zhang Y; Liu H; Jiang H; Ge H; Zhang Y
    Pediatr Cardiol; 2017 Oct; 38(7):1450-1455. PubMed ID: 28755092
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New antiarrhythmic drug in pediatric use: sotalol.
    Pfammatter JP; Paul T
    Pediatr Cardiol; 1997; 18(1):28-34. PubMed ID: 8960489
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sotalol: Current Status and Expanding Indications.
    Singh BN
    J Cardiovasc Pharmacol Ther; 1999 Jan; 4(1):49-65. PubMed ID: 10684524
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Implementation of an intravenous sotalol initiation protocol: Implications for feasibility, safety, and length of stay.
    Liu AY; Charron J; Fugaro D; Spoolstra S; Kaplan R; Lohrmann G; Gao X; Gay H; Passman R; Kim S; Lin AC; Chicos A; Arora R; Patil K; Pfenniger A; Knight BP; Verma N
    J Cardiovasc Electrophysiol; 2023 Mar; 34(3):502-506. PubMed ID: 36640424
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term sotalol therapy in patients with ventricular arrhythmias.
    Mary-Rabine L; Soumagne D; Stiels B
    Acta Cardiol; 1986; 41(2):89-97. PubMed ID: 2424202
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anti-arrhythmic actions of -adrenergic receptor antagonists: review of fundamental aspects.
    Singh BN
    N Z Med J; 1972 Nov; 76(486):333-42. PubMed ID: 4405558
    [No Abstract]   [Full Text] [Related]  

  • 30. Sotalol.
    Kpaeyeh JA; Wharton JM
    Card Electrophysiol Clin; 2016 Jun; 8(2):437-52. PubMed ID: 27261833
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sotalol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use.
    Singh BN; Deedwania P; Nademanee K; Ward A; Sorkin EM
    Drugs; 1987 Sep; 34(3):311-49. PubMed ID: 3315621
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sotalol: a novel beta-blocker with class III anti-arrhythmic activity.
    Leibowitz D
    J Clin Pharmacol; 1993 Jun; 33(6):508-12. PubMed ID: 8366175
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Treatment of acute cardiac arrhythmias using adrenergic beta blockaders. Experience with sotalol].
    Martín Jadraque L; Liste Jiménez D; González Maqueda I; Del Rio Bustos A
    Rev Esp Cardiol; 1975; 38(2):153-62. PubMed ID: 1135483
    [No Abstract]   [Full Text] [Related]  

  • 34. [Evaluation of antiarrhythmic efficacy of sotalol in various doses in patients with ventricular tachyarrhythmias].
    Luczak D; Dabrowski R; Szwed H; Gasior Z; Stanke A; Jasek S; Skrabucha B; Matar A; Kowalik I
    Pol Merkur Lekarski; 1997 Feb; 2(8):122-5. PubMed ID: 9538657
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Effect of sotalol on systemic hemodynamics and electrophysiology in patients with life-threatening ventricular tachyarrhythmias].
    Fu G; Shan J; Wille B
    Zhonghua Nei Ke Za Zhi; 1999 Jan; 38(1):30-2. PubMed ID: 11798623
    [TBL] [Abstract][Full Text] [Related]  

  • 36. QT prolongation and serum sotalol concentration are highly correlated following intravenous and oral sotalol.
    Somberg JC; Preston RA; Ranade V; Molnar J
    Cardiology; 2010; 116(3):219-25. PubMed ID: 20693799
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Concentration-dependent pharmacologic properties of sotalol.
    Wang T; Bergstrand RH; Thompson KA; Siddoway LA; Duff HJ; Woosley RL; Roden DM
    Am J Cardiol; 1986 May; 57(13):1160-5. PubMed ID: 3706170
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and proarrhythmia of oral sotalol in pediatric patients.
    Pfammatter JP; Paul T; Lehmann C; Kallfelz HC
    J Am Coll Cardiol; 1995 Oct; 26(4):1002-7. PubMed ID: 7560592
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Early experience with intravenous sotalol in children with and without congenital heart disease.
    Valdés SO; Miyake CY; Niu MC; de la Uz CM; Asaki SY; Landstrom AP; Schneider AE; Rusin CG; Patel R; Lam WW; Kim JJ
    Heart Rhythm; 2018 Dec; 15(12):1862-1869. PubMed ID: 30003959
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sotalol.
    Ruffy R
    J Cardiovasc Electrophysiol; 1993 Feb; 4(1):81-98. PubMed ID: 8287239
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.